- Home
- CIX vs CRDF Comparison
CIX vs CRDF Comparison
Compare CIX & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIX
- CRDF
- Stock Information
- Founded
- CIX 1993
- CRDF 1999
- Country
- CIX United States
- CRDF United States
- Employees
- CIX N/A
- CRDF N/A
- Industry
- CIX Industrial Machinery/Components
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIX Consumer Discretionary
- CRDF Health Care
- Exchange
- CIX Nasdaq
- CRDF Nasdaq
- Market Cap
- CIX N/A
- CRDF 288.7M
- IPO Year
- CIX 1998
- CRDF N/A
- Fundamental
- Price
- CIX $22.09
- CRDF $3.73
- Analyst Decision
- CIX
- CRDF Strong Buy
- Analyst Count
- CIX 0
- CRDF 4
- Target Price
- CIX N/A
- CRDF $12.00
- AVG Volume (30 Days)
- CIX 7.5K
- CRDF 1.2M
- Earning Date
- CIX 03-05-2025
- CRDF 05-01-2025
- Dividend Yield
- CIX 5.44%
- CRDF N/A
- EPS Growth
- CIX N/A
- CRDF N/A
- EPS
- CIX 1.35
- CRDF N/A
- Revenue
- CIX $145,941,000.00
- CRDF $683,000.00
- Revenue This Year
- CIX N/A
- CRDF N/A
- Revenue Next Year
- CIX N/A
- CRDF N/A
- P/E Ratio
- CIX $16.49
- CRDF N/A
- Revenue Growth
- CIX N/A
- CRDF 39.96
- 52 Week Low
- CIX $20.60
- CRDF $2.01
- 52 Week High
- CIX $37.91
- CRDF $6.38
- Technical
- Relative Strength Index (RSI)
- CIX 43.22
- CRDF 45.87
- Support Level
- CIX $21.65
- CRDF $3.65
- Resistance Level
- CIX $22.55
- CRDF $3.88
- Average True Range (ATR)
- CIX 0.99
- CRDF 0.26
- MACD
- CIX 0.09
- CRDF -0.02
- Stochastic Oscillator
- CIX 50.28
- CRDF 30.00
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").